BELL & LINDSAY, INC.

Lobbying for DEMERX, INC · Clinical stage drug development company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Florida · House · Senate · $5,000.00 income · posted Jun 30, 2025

Lobbying activity 1

Health Issues

advocacy and education around the company's value proposition to advance medicines to break the cycle of alcohol and drug dependence.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.